| NCT01129596Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease- | Donepezil Alzheimer’s disease | Alzheimer's disease | Not applicable | Completed | 722 | Sep 2015 | 1 | |
| EVOKE PlusA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Semaglutide Alzheimer’s disease | CDR global 0.5 | Ph 3 | Completed | 498 | Sep 2025 | 4 | |
| EVOKEA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Semaglutide Alzheimer’s disease | CDR global 0.5 | Ph 3 | Completed | 447 | Sep 2025 | 3 | |
| NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Xanomeline / trospium Alzheimer’s disease | Age 55-90 | Ph 3 | Recruiting | 429 | Sep 2027 | - | |
| NCT00667810Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients | Bapineuzumab Alzheimer’s disease | Alzheimer's disease | Ph 3 | Terminated | 346 | Oct 2012 | 2 | results |
| NCT04241068A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 | Aducanumab Alzheimer’s disease | Age 50-90 | Ph 3 | Terminated | 297 | Jul 2024 | - | results |
| NCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Xanomeline / trospium Alzheimer’s disease | Alzheimer's disease | Ph 3 | Recruiting | 292 | Nov 2026 | - | |
| NCT00676143Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients | Bapineuzumab Alzheimer’s disease | Alzheimer's disease | Ph 3 | Terminated | 288 | Oct 2012 | 2 | results |
| NCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | Donanemab Alzheimer’s disease | MMSE 20-28 | Ph 3 | Active, not recruiting | 274 | Apr 2023 | 13 | results |
| NCT00490568Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers | Rosiglitazone Alzheimer’s disease | Age 51-91 | Ph 3 | Terminated | 272 | Jun 2009 | 1 | results |
| NCT04374253A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) | Gantenerumab Alzheimer’s disease | Study partner/caregiver required | Ph 3 | Terminated | 268 | Mar 2023 | 1 | results |
| ENVISIONA Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease | Aducanumab Alzheimer’s disease | MCI due to AD | Ph 3 | Terminated | 265 | Aug 2024 | - | results |
| DAYBREAK-ALZA Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia | Lanabecestat Alzheimer’s disease | mild AD dementia | Ph 3 | Terminated | 262 | Sep 2018 | 2 | results |
| NCT06653153A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) | Remternetug Alzheimer’s disease | Amyloid biomarker required | Ph 3 | Active, not recruiting | 262 | Apr 2029 | - | |
| STAR ExtensionLong-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease | Idalopirdine Alzheimer’s disease | Age ≥50 | Ph 3 | Completed | 258 | Jul 2017 | - | results |
| MissionAD1A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease | Elenbecestat Alzheimer’s disease | MCI due to AD / mild AD dementia | Ph 3 | Terminated | 258 | Jan 2020 | 3 | results |
| NCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Xanomeline, Xanomeline / trospium Alzheimer’s disease | Study partner/caregiver required | Ph 3 | Recruiting | 256 | Jun 2029 | - | |
| AMARANTHAn Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease | Lanabecestat Alzheimer’s disease | MCI due to AD | Ph 2/3 | Terminated | 254 | Oct 2018 | 4 | results |
| NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) | Bapineuzumab Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 251 | Jun 2012 | 6 | |
| REFLECT-2Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease | Donepezil, Rosiglitazone Alzheimer’s disease | mild-to-moderate AD | Not applicable | Completed | 249 | Jan 2009 | 1 | results |
| Clarity ADA Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Lecanemab Alzheimer’s disease | MCI due to AD / mild AD dementia | Ph 3 | Active, not recruiting | 247 | Jun 2029 | 8 | |
| NCT02446132Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | AVP-786 Alzheimer’s disease | Alzheimer's disease | Ph 3 | Terminated | 227 | Sep 2024 | - | results |
| NCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Donanemab Alzheimer’s disease | Amyloid biomarker required | Ph 3 | Active, not recruiting | 216 | Nov 2027 | 1 | |
| CREAD 2A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) | Crenezumab Alzheimer’s disease | prodromal AD | Ph 3 | Terminated | 211 | Jun 2019 | 4 | results |
| NCT03393520Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | AVP-786 Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 211 | Nov 2023 | - | |
